Do analysts recommend SLDB or YDES?

Solid Biosciences currently has a consensus price target of $18.18, suggesting a potential upside of 100.46%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Solid Biosciences is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.83 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, SLDB or YDES?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.91 N/A YD Bio N/A N/A N/A N/A N/A

Is SLDB or YDES more profitable?

YD Bio's return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% YD Bio N/A N/A N/A

Does the media favor SLDB or YDES?

In the previous week, YD Bio had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for YD Bio and 3 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.82 beat YD Bio's score of 1.07 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CVAC or YDES?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CVAC or YDES?

CureVac has higher revenue and earnings than YD Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 YD Bio N/A N/A N/A N/A N/A

Is CVAC or YDES more profitable?

CureVac has a net margin of 199.92% compared to YD Bio's net margin of 0.00%. YD Bio's return on equity of 0.00% beat CureVac's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% YD Bio N/A N/A N/A

Do analysts prefer YDES or AVTX?

Avalo Therapeutics has a consensus price target of $45.10, suggesting a potential upside of 162.51%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.85

Which has better valuation and earnings, YDES or AVTX?

YD Bio has higher earnings, but lower revenue than Avalo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Avalo Therapeutics $60K 15,356.06 -$78.26M -$4.37 N/A

Is YDES or AVTX more profitable?

YD Bio's return on equity of 0.00% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Avalo Therapeutics N/A -58.03% -48.22%

Does the media favor YDES or AVTX?

In the previous week, Avalo Therapeutics had 5 more articles in the media than YD Bio. MarketBeat recorded 9 mentions for Avalo Therapeutics and 4 mentions for YD Bio. YD Bio's average media sentiment score of 1.07 beat Avalo Therapeutics' score of 0.96 indicating that YD Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ABUS or YDES?

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential downside of 2.34%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Arbutus Biopharma is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ABUS or YDES?

YD Bio has lower revenue, but higher earnings than Arbutus Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arbutus Biopharma $14.08M 72.04 -$33.50M $0.79 6.48 YD Bio N/A N/A N/A N/A N/A

Does the media refer more to ABUS or YDES?

In the previous week, YD Bio had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for YD Bio and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat YD Bio's score of 1.07 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend YDES or IMMX?

Immix Biopharma has a consensus price target of $21.29, indicating a potential upside of 67.60%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Immix Biopharma is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immix Biopharma 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78

Which has preferable valuation & earnings, YDES or IMMX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Immix Biopharma N/A N/A -$29.44M -$0.88 N/A

Is YDES or IMMX more profitable?

YD Bio's return on equity of 0.00% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Immix Biopharma N/A -38.44% -34.72%

Does the media favor YDES or IMMX?

In the previous week, Immix Biopharma had 2 more articles in the media than YD Bio. MarketBeat recorded 6 mentions for Immix Biopharma and 4 mentions for YD Bio. Immix Biopharma's average media sentiment score of 1.16 beat YD Bio's score of 1.07 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

YD Bio (YDES) Competitors

$3.90 -0.02 (-0.51%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$3.78 -0.12 (-3.08%)

As of 09/10/2026 07:30 PM Eastern

Compare

YDES vs. SLDB, CVAC, AVTX, ABUS, and IMMX

Should you buy YD Bio stock or one of its competitors? YD Bio's main competitors and comparable companies include Solid Biosciences (SLDB), CureVac (CVAC), Avalo Therapeutics (AVTX), Arbutus Biopharma (ABUS), and Immix Biopharma (IMMX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does YD Bio compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

YD Bio's return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
YD Bio	N/A	N/A	N/A

In the previous week, YD Bio had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for YD Bio and 3 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.82 beat YD Bio's score of 1.07 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences currently has a consensus price target of $18.18, suggesting a potential upside of 100.46%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Solid Biosciences is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

81.5% of Solid Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Solid Biosciences beats YD Bio on 6 of the 9 factors compared between the two stocks.

How does YD Bio compare to CureVac?

CureVac (NASDAQ:CVAC) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

CureVac has higher revenue and earnings than YD Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
YD Bio	N/A	N/A	N/A	N/A	N/A

In the previous week, YD Bio had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for YD Bio and 0 mentions for CureVac. YD Bio's average media sentiment score of 1.07 beat CureVac's score of 0.00 indicating that YD Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
YD Bio	Positive

CureVac has a net margin of 199.92% compared to YD Bio's net margin of 0.00%. YD Bio's return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
YD Bio	N/A	N/A	N/A

17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CureVac and YD Bio tied by winning 4 of the 8 factors compared between the two stocks.

How does YD Bio compare to Avalo Therapeutics?

YD Bio (NASDAQ:YDES) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Avalo Therapeutics has a consensus price target of $45.10, suggesting a potential upside of 162.51%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Avalo Therapeutics had 5 more articles in the media than YD Bio. MarketBeat recorded 9 mentions for Avalo Therapeutics and 4 mentions for YD Bio. YD Bio's average media sentiment score of 1.07 beat Avalo Therapeutics' score of 0.96 indicating that YD Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

YD Bio has higher earnings, but lower revenue than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Avalo Therapeutics	$60K	15,356.06	-$78.26M	-$4.37	N/A

YD Bio's return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Avalo Therapeutics	N/A	-58.03%	-48.22%

Summary

Avalo Therapeutics beats YD Bio on 7 of the 10 factors compared between the two stocks.

How does YD Bio compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

In the previous week, YD Bio had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for YD Bio and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat YD Bio's score of 1.07 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

YD Bio has lower revenue, but higher earnings than Arbutus Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	72.04	-$33.50M	$0.79	6.48
YD Bio	N/A	N/A	N/A	N/A	N/A

43.8% of Arbutus Biopharma shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arbutus Biopharma has a net margin of 84.22% compared to YD Bio's net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat YD Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
YD Bio	N/A	N/A	N/A

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential downside of 2.34%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Arbutus Biopharma is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Arbutus Biopharma beats YD Bio on 10 of the 11 factors compared between the two stocks.

How does YD Bio compare to Immix Biopharma?

YD Bio (NASDAQ:YDES) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

In the previous week, Immix Biopharma had 2 more articles in the media than YD Bio. MarketBeat recorded 6 mentions for Immix Biopharma and 4 mentions for YD Bio. Immix Biopharma's average media sentiment score of 1.16 beat YD Bio's score of 1.07 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma has a consensus price target of $21.29, indicating a potential upside of 67.60%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Immix Biopharma is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

11.3% of Immix Biopharma shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

YD Bio's return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Immix Biopharma	N/A	-38.44%	-34.72%

Summary

Immix Biopharma beats YD Bio on 7 of the 9 factors compared between the two stocks.

Get YD Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YDES and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YDES vs. The Competition

Export

Metric	YD Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$277.85M	$3.88B	$7.21B	$12.81B
Dividend Yield	N/A	3.63%	2.56%	10.55%
P/E Ratio	N/A	13.60	272.83	25.11
Price / Sales	N/A	1,340.82	623.31	90.53
Price / Cash	N/A	106.61	77.33	51.83
Price / Book	N/A	15.30	10.38	6.18
Net Income	N/A	-$22.82M	$3.49B	$358.18M
7 Day Performance	10.17%	-3.93%	-3.16%	-2.51%
1 Month Performance	42.86%	0.29%	0.02%	-2.73%
1 Year Performance	N/A	38.63%	17.32%	7.73%

YD Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YDES YD Bio	1.6654 of 5 stars	$3.90 -0.5%	N/A	N/A	$277.85M	N/A	N/A	N/A	Positive News Gap Down High Trading Volume
SLDB Solid Biosciences	2.5378 of 5 stars	$10.28 +4.0%	$18.18 +76.9%	+73.1%	$1.06B	N/A	N/A	100	Gap Down
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
AVTX Avalo Therapeutics	3.8082 of 5 stars	$19.34 +2.1%	$45.10 +133.2%	+55.9%	$1.02B	$59K	N/A	40
ABUS Arbutus Biopharma	1.5844 of 5 stars	$5.10 +0.2%	$5.00 -2.0%	+10.8%	$1.01B	$14.08M	6.46	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YDES) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

YD Bio (YDES) Competitors

YDES vs. SLDB, CVAC, AVTX, ABUS, and IMMX

How does YD Bio compare to Solid Biosciences?

Summary

How does YD Bio compare to CureVac?

Summary

How does YD Bio compare to Avalo Therapeutics?

Summary

How does YD Bio compare to Arbutus Biopharma?

Summary

How does YD Bio compare to Immix Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES vs. The Competition

YD Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

YD Bio (YDES) Competitors

YDES vs. SLDB, CVAC, AVTX, ABUS, and IMMX

How does YD Bio compare to Solid Biosciences?

Is SLDB or YDES more profitable?

Does the media favor SLDB or YDES?

Do analysts recommend SLDB or YDES?

Which has higher valuation and earnings, SLDB or YDES?

Do insiders & institutionals hold more shares of SLDB or YDES?

Summary

How does YD Bio compare to CureVac?

Which has stronger valuation and earnings, CVAC or YDES?

Does the media prefer CVAC or YDES?

Is CVAC or YDES more profitable?

Do institutionals and insiders hold more shares of CVAC or YDES?

Do analysts rate CVAC or YDES?

Summary

How does YD Bio compare to Avalo Therapeutics?

Do analysts prefer YDES or AVTX?

Do institutionals and insiders hold more shares of YDES or AVTX?

Does the media favor YDES or AVTX?

Which has better valuation and earnings, YDES or AVTX?

Is YDES or AVTX more profitable?

Summary

How does YD Bio compare to Arbutus Biopharma?

Does the media refer more to ABUS or YDES?

Which has higher earnings and valuation, ABUS or YDES?

Do institutionals & insiders believe in ABUS or YDES?

Is ABUS or YDES more profitable?

Do analysts prefer ABUS or YDES?

Summary

How does YD Bio compare to Immix Biopharma?

Which has preferable valuation & earnings, YDES or IMMX?

Does the media favor YDES or IMMX?

Do analysts recommend YDES or IMMX?

Do institutionals and insiders believe in YDES or IMMX?

Is YDES or IMMX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES vs. The Competition

YD Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools